BLUETTI
12.3.2024 10:01:26 CET | Business Wire | Press release
BLUETTI, the leading innovator in sustainable energy solutions, is thrilled to announce the upcoming launch of its latest product, the BLUETTI AC200L Portable Power Station, set to hit the European market on March 13. Designed to revolutionize portable power, the AC200L is a powerhouse of reliability, efficiency, and eco-friendliness.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240312603366/en/
BLUETTI NEW COLLECTION AC200L (Photo: Business Wire)
Unrivaled Power and Durability
At the heart of the BLUETTI AC200L lies a robust 2,048Wh Lithium Iron Phosphate (LiFePO₄) battery, ensuring longevity and safety for over a decade with more than 3,000 life cycles. BLUETTI also backs it with an industry-leading 5-year warranty for added peace of mind. Equipped with a formidable 2,400W pure sine wave AC inverter(7,200W surge), extendable to 3,600W in Power Lifting mode, the AC200L is primed to handle high-demand appliances and sensitive electronics with ease.
Extendable Capacity and Fast Charging
The AC200L can independently power a 1,200W coffee maker, brewing about 31 cups of fresh coffee, and sustain a 150W fridge for over 12 hours. Additionally, it supports capacity expansion through extra batteries like the 2,048Wh B230 or two 3,072Wh B300 battery packs. This boosts its capacity to 4,096Wh or 8,192Wh, respectively, prolonging its runtime as required.
With 2,400W of fast charge capability, the AC200L can reach an 80% charge from the wall in as little as 45 minutes. In optimal weather conditions, it completes a 1,200W solar charge in approximately 2 hours, perfect for backup and on-the-go power needs.
Versatile Outlets and Intelligent Features
The AC200L boasts 10 outlets for diverse power needs, including a 48V DC port for RV life battery charging when paired with the optional BLUETTI D40 DC-DC charger, which can convert 12V power for most RV devices.
Moreover, users can adjust these settings and monitor/manage the battery via the BLUETTI app.
About BLUETTI
Committed to a sustainable future, BLUETTI has pioneered affordable green energy storage solutions for both indoor and outdoor use. Through initiatives like the LAAF (Lighting An African Family) program, BLUETTI will empower over 100,000 African families in rural areas, providing well-lit living spaces and equal learning opportunities. With an extensive and reliable product portfolio tailored for adventures, emergency backup power, and off-grid living, BLUETTI continues to make a tangible and positive impact on minimizing our carbon footprint worldwide. For more information on BLUETTI and its innovative products, visit BLUETTI's website.
Source: BLUETTI EU Marketing
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240312603366/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom